相似文献
1
Expanding the range of 'druggable' targets with natural product-based libraries: an academic perspective.
Curr Opin Chem Biol. 2010 Jun;14(3):308-14. doi: 10.1016/j.cbpa.2010.02.001. Epub 2010 Mar 2.
2
Fragment-based screening with natural products for novel anti-parasitic disease drug discovery.
Expert Opin Drug Discov. 2019 Dec;14(12):1283-1295. doi: 10.1080/17460441.2019.1653849. Epub 2019 Sep 12.
3
Cheminformatics approaches to analyze diversity in compound screening libraries.
Curr Opin Chem Biol. 2010 Jun;14(3):325-30. doi: 10.1016/j.cbpa.2010.03.017. Epub 2010 Apr 22.
4
Revisiting Pyrimidine-Embedded Molecular Frameworks to Probe the Unexplored Chemical Space for Protein-Protein Interactions.
Acc Chem Res. 2024 Nov 19;57(22):3254-3265. doi: 10.1021/acs.accounts.4c00452. Epub 2024 Oct 31.
5
Enhancements of screening collections to address areas of unmet medical need: an industry perspective.
Curr Opin Chem Biol. 2010 Jun;14(3):289-98. doi: 10.1016/j.cbpa.2010.03.024. Epub 2010 Apr 21.
6
[Chemical libraries dedicated to protein-protein interactions].
Med Sci (Paris). 2015 Mar;31(3):312-9. doi: 10.1051/medsci/20153103017. Epub 2015 Apr 8.
7
Rationally minimizing natural product libraries using mass spectrometry.
mSystems. 2025 Mar 18;10(3):e0084424. doi: 10.1128/msystems.00844-24. Epub 2025 Feb 24.
8
Drugging challenging targets using fragment-based approaches.
Curr Opin Chem Biol. 2010 Jun;14(3):299-307. doi: 10.1016/j.cbpa.2010.02.010. Epub 2010 Mar 10.
9
Building upon Nature's Framework: Overview of Key Strategies Toward Increasing Drug-Like Properties of Natural Product Cyclopeptides and Macrocycles.
Methods Mol Biol. 2019;2001:203-233. doi: 10.1007/978-1-4939-9504-2_10.
10
Chemical proteomics: terra incognita for novel drug target profiling.
Chin J Cancer. 2012 Nov;31(11):507-18. doi: 10.5732/cjc.011.10377. Epub 2012 May 23.
引用本文的文献
1
Pseudonatural Products for Chemical Biology and Drug Discovery.
J Med Chem. 2025 Jul 24;68(14):14137-14170. doi: 10.1021/acs.jmedchem.5c00643. Epub 2025 Jul 1.
2
Discovery of a novel binding pocket in PPARγ for partial agonists: structure-based virtual screening identifies ginsenoside Rg5 as a partial agonist promoting beige adipogenesis.
Front Chem. 2025 May 8;13:1579445. doi: 10.3389/fchem.2025.1579445. eCollection 2025.
3
Antibacterial Potential of Ethyl 3,5-Dibromoorsellinate, a Derivative of Diphenyl Ethers from , against Methicillin-Resistant .
ACS Omega. 2024 Dec 3;9(50):50012-50023. doi: 10.1021/acsomega.4c09518. eCollection 2024 Dec 17.
4
A divergent intermediate strategy yields biologically diverse pseudo-natural products.
Nat Chem. 2024 Jun;16(6):945-958. doi: 10.1038/s41557-024-01458-4. Epub 2024 Feb 16.
5
Clinical development and informatics analysis of natural and semi-synthetic flavonoid drugs: A critical review.
J Adv Res. 2024 Sep;63:269-284. doi: 10.1016/j.jare.2023.11.007. Epub 2023 Nov 8.
6
Biocatalysis in Drug Design: Engineered Reductive Aminases (RedAms) Are Used to Access Chiral Building Blocks with Multiple Stereocenters.
J Am Chem Soc. 2023 Oct 11;145(40):22041-22046. doi: 10.1021/jacs.3c07010. Epub 2023 Oct 2.
7
High-Throughput Screening of Natural Product and Synthetic Molecule Libraries for Antibacterial Drug Discovery.
Metabolites. 2023 May 2;13(5):625. doi: 10.3390/metabo13050625.
8
The Time and Place for Nature in Drug Discovery.
JACS Au. 2022 Oct 14;2(11):2400-2416. doi: 10.1021/jacsau.2c00415. eCollection 2022 Nov 28.
9
The Inhibitors of CDK4/6 from a Library of Marine Compound Database: A Pharmacophore, ADMET, Molecular Docking and Molecular Dynamics Study.
Mar Drugs. 2022 May 12;20(5):319. doi: 10.3390/md20050319.
10
Investigation of Marine-Derived Natural Products as Raf Kinase Inhibitory Protein (RKIP)-Binding Ligands.
Mar Drugs. 2021 Oct 18;19(10):581. doi: 10.3390/md19100581.
本文引用的文献
1
Syntheses of aminoalcohol-derived macrocycles leading to a small-molecule binder to and inhibitor of Sonic Hedgehog.
Bioorg Med Chem Lett. 2009 Nov 15;19(22):6319-25. doi: 10.1016/j.bmcl.2009.09.089. Epub 2009 Sep 25.
2
Antibiotics for emerging pathogens.
Science. 2009 Aug 28;325(5944):1089-93. doi: 10.1126/science.1176667.
3
Mimicking the BH3 domain to kill cancer cells.
Oncogene. 2008 Dec;27 Suppl 1(0 1):S149-57. doi: 10.1038/onc.2009.52.
4
Chemistry and biology of non-tetramic gamma-hydroxy-gamma-lactams and gamma-alkylidene-gamma-lactams from natural sources.
Nat Prod Rep. 2009 Aug;26(8):1044-62. doi: 10.1039/b903905h. Epub 2009 Jun 11.
5
Quantifying biogenic bias in screening libraries.
Nat Chem Biol. 2009 Jul;5(7):479-83. doi: 10.1038/nchembio.180. Epub 2009 May 31.
6
The spliceosome: design principles of a dynamic RNP machine.
Cell. 2009 Feb 20;136(4):701-18. doi: 10.1016/j.cell.2009.02.009.
7
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.
Clin Cancer Res. 2009 Feb 15;15(4):1126-32. doi: 10.1158/1078-0432.CCR-08-0144.
8
A small molecule that binds Hedgehog and blocks its signaling in human cells.
Nat Chem Biol. 2009 Mar;5(3):154-6. doi: 10.1038/nchembio.142. Epub 2009 Jan 18.
9
Inhibition of transcription factors with small organic molecules.
Curr Opin Chem Biol. 2008 Aug;12(4):464-71. doi: 10.1016/j.cbpa.2008.07.023. Epub 2008 Aug 13.
10
The exploration of macrocycles for drug discovery--an underexploited structural class.
Nat Rev Drug Discov. 2008 Jul;7(7):608-24. doi: 10.1038/nrd2590.
Zotero 插件